Patients with, volume overload and that its action was not associated.With electrolyte imbalance or renal impairment.18 The.Presence of worsening congestive symptoms is a leading cause.Of hospitalization and reduction, in the patient 's quality of life. 19.In the QUEST study improvement of, congestive symptoms was.Also reported.18.However the applicability, of the results of the QUEST study.Is limited by the clinical trial 's strict inclusion and exclusion.Criteria for enrollment. Therefore it is, desirable to confirm.Whether the efficacy and safety features of tolvaptan in clinical.Trials can be extended to real-world clinical settings. Hence the.Aim of this study was to provide efficacy and safety data from.Post-marketing surveillance of tolvaptan in HF patients with.Volume overload. Hypernatremia is a major and unique concern.With tolvaptan because of its aquaretic nature and a, risk analysis.Was executed to predict the occurrence of hypernatremia.After tolvaptan treatment.
การแปล กรุณารอสักครู่..
